ArticleInternational journal of nanomedicine2017
Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Schisandrin B confers multi-organ protection via regulation of mitochondrial homeostasis: mechanistic integration, organ-specific differences, and translational challenges-a review.Frontiers in pharmacology · 2026Review
- The future of cardiac repair: a review on cell-free nanotherapies for regenerative myocardial infarction.Drug delivery and translational research · 2025Review
- Ceria nanoparticles alleviate myocardial ischemia-reperfusion injury by inhibiting cardiomyocyte apoptosis via alleviating ROS mediated excessive mitochondrial fission.Materials today. Bio · 2025Article
- A comprehensive review of Schisandrin B's preclinical antitumor activity and mechanistic insights from network pharmacology.Frontiers in pharmacology · 2025Review
- Intravascularly Deliverable Biomaterial Platforms for Tissue Repair and Regeneration Post-Myocardial Infarction.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- A bibliometric study related to the treatment of myocardial ischemia-reperfusion Injury.Journal of cardiothoracic surgery · 2024Article
- Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction.Molecules (Basel, Switzerland) · 2024Review
- A comprehensive review on Schisandrin and its pharmacological features.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Biomaterials-Based Antioxidant Strategies for the Treatment of Oxidative Stress Diseases.Biomimetics (Basel, Switzerland) · 2024Review
- Nanomedicines as Guardians of the Heart: Unleashing the Power of Antioxidants to Alleviate Myocardial Ischemic Injury.Theranostics · 2024Review
- Advanced Nanomedicine Approaches for Myocardial Infarction Treatment.International journal of nanomedicine · 2024Review
- The traditional Chinese medicines treat chronic heart failure and their main bioactive constituents and mechanisms.Acta pharmaceutica Sinica. B · 2023Review
- Scavenger receptor A-mediated nanoparticles target M1 macrophages for acute liver injury.Asian journal of pharmaceutical sciences · 2023Article
- Gene Therapy for Cardiomyocyte Renewal: Cell Cycle, a Potential Therapeutic Target.Molecular diagnosis & therapy · 2023Article
- Article
- Nanocarrier-Based Targeted Therapies for Myocardial Infarction.Pharmaceutics · 2022Review
- Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries.Bioactive materials · 2022Review
- Nanomaterials-Mediated Therapeutics and Diagnosis Strategies for Myocardial Infarction.Frontiers in chemistry · 2022Review
- Acute myocardial infarction therapy:Drug delivery · 2021Article
- Biologics and their delivery systems: Trends in myocardial infarction.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSchisandrin B (Sch B) is clinically applied for the treatment of hepatitis and ischemic disease. However, its clinical efficacy is limited due to the poor solubility and low bioavailability. This study aimed to develop matrix metalloproteinase (MMP)-sensitive peptide-modified, polyethylene glycol (PEG)-modified (PEGylated) solid lipid nanoparticles (SLNs) for loading Sch B (MMP-Sch B SLNs), and to evaluate the therapeutic effect in the myocardial infarction model.
methodsPEG lipid and MMP-targeting peptide conjugate were synthesized. MMP-Sch B SLNs were prepared by solvent displacement technique. The physicochemical properties and pharmacokinetics of SLNs were investigated. In vivo effects on infarct size was evaluated in rats.
resultsThe successful synthesis of lipid-peptide conjugate was confirmed. MMP-Sch B SLNs had a particle size of 130 nm, a zeta potential of 18.3 mV, and a sustained-release behavior. Higher heart drug concentration and longer blood circulation times were achieved by Sch B loaded SLNs than the drug solution according to the pharmacokinetic and biodistribution results. The best therapeutic efficacy was exhibited by MMP-Sch B SLNs by reducing the infarction size to the greatest extent.
conclusionThe modified SLNs may be a good choice for delivery of Sch B for the treatment of myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.